Literature DB >> 26866499

Botulinum Toxin Treatment of Neuropathic Pain.

Shivam Om Mittal1, Delaram Safarpour2, Bahman Jabbari3.   

Abstract

Neuropathic pain (NP), a common form of human pain, often poorly responds to analgesic medications. In this review the authors discuss the pathophysiology and conventional treatment of neuropathic pain and provide evidenced-based statements on the efficacy of botulinum neurotoxins (BoNTs) in this form of pain. The level of efficacy for BoNT treatment in each category of NP is defined according to the published guidelines of the American Academy of Neurology. The data indicate that BoNT treatment (most of the literature is with onabotulinumtoxinA) is effective (level A evidence) in postherpetic neuralgia and trigeminal neuralgia. It is probably effective (level B) in posttraumatic neuralgia and painful diabetic neuropathy. The data on complex regional pain syndrome, carpal tunnel syndrome, occipital neuralgia, and phantom limb pain are preliminary and await conduction of randomized, blinded clinical trials. Much remains to be learned about the most-effective dosage and technique of injection, optimum dilutions, and differences among BoNTs in the treatment of neuropathic pain. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26866499     DOI: 10.1055/s-0036-1571953

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  10 in total

Review 1.  Coping with Phantom Limb Pain.

Authors:  Damien P Kuffler
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

Review 2.  Atypical Facial Pain: a Comprehensive, Evidence-Based Review.

Authors:  Austin L Weiss; Ken P Ehrhardt; Reda Tolba
Journal:  Curr Pain Headache Rep       Date:  2017-02

3.  Update on Interventional Management of Neuropathic Pain: A Delphi Consensus of the Spanish Pain Society Neuropathic Pain Task Force.

Authors:  Ancor Serrano-Afonso; Rafael Gálvez; Elena Paramés; Ana Navarro; Dolores Ochoa; Concepción Pérez-Hernández
Journal:  Medicina (Kaunas)       Date:  2022-04-30       Impact factor: 2.948

4.  Periorbital botulinum toxin A improves photophobia and sensations of dryness in patients without migraine: Case series of four patients.

Authors:  Nandini Venkateswaran; Jodi Hwang; Andrew J Rong; Alexandra E Levitt; Ryan J Diel; Roy C Levitt; Konstantinos D Sarantopoulos; Wendy W Lee; Anat Galor
Journal:  Am J Ophthalmol Case Rep       Date:  2020-07-04

5.  Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies.

Authors:  Jessica Kopenhaver; Robert D Carlson; Adam E Snook
Journal:  Toxins (Basel)       Date:  2020-06-23       Impact factor: 4.546

6.  Ultrasound-guided peripheral nerve interventions for common pain disorders.

Authors:  B P Krishna Prasad; Binu Joy; Vijayakumar A Raghavendra; Ajith Toms; Danny George; Brijesh Ray
Journal:  Indian J Radiol Imaging       Date:  2018 Jan-Mar

7.  Botulinum Toxin in Restless Legs Syndrome-A Randomized Double-Blind Placebo-Controlled Crossover Study.

Authors:  Shivam Om Mittal; Duarte Machado; Diana Richardson; Divyanshu Dubey; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2018-09-29       Impact factor: 4.546

Review 8.  Botulinum Neurotoxins and Cancer-A Review of the Literature.

Authors:  Shivam Om Mittal; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2020-01-05       Impact factor: 4.546

9.  Intramuscular Botulinum toxin A injections induce central changes to axon initial segments and cholinergic boutons on spinal motoneurones in rats.

Authors:  D B Jensen; S Klingenberg; K P Dimintiyanova; J Wienecke; C F Meehan
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

10.  Efficacy and safety of botulinum toxin type A in distraction osteogenesis of the lower extremities: a meta-analysis of randomized controlled trials.

Authors:  Yu-Chi Su; Yao-Hong Guo; Pei-Chun Hsieh; Yu-Ching Lin
Journal:  BMC Musculoskelet Disord       Date:  2022-03-25       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.